The role of glucagon‐like peptide‐1 impairment in obesity and potential therapeutic implications
S Madsbad - Diabetes, Obesity and Metabolism, 2014 - Wiley Online Library
The hormone glucagon‐like peptide‐1 (GLP‐1) is released from the gut in response to food
intake. It acts as a satiety signal, leading to reduced food intake, and also as a regulator of …
intake. It acts as a satiety signal, leading to reduced food intake, and also as a regulator of …
Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients
OBJECTIVE—To quantitate the separate impact of obesity and hyperlycemia on the incretin
effect (ie, the gain in β-cell function after oral glucose versus intravenous glucose) …
effect (ie, the gain in β-cell function after oral glucose versus intravenous glucose) …
[PDF][PDF] DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes
CF Deacon, RD Carr, JJ Holst - Front Biosci, 2008 - article.imrpress.com
Introduction 3. Incretins and glucose regulation in health and disease 3.1. Pancreatic islet
mass and function 3.2. Incretin actions 3.3. The incretin effect 3.4. The incretin receptors 4 …
mass and function 3.2. Incretin actions 3.3. The incretin effect 3.4. The incretin receptors 4 …
Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?
FK Knop, T Vilsbøll, PV Højberg, S Larsen… - Diabetes, 2007 - Am Diabetes Assoc
We aimed to investigate whether the reduced incretin effect observed in patients with type 2
diabetes is a primary event in the pathogenesis of type 2 diabetes or a consequence of the …
diabetes is a primary event in the pathogenesis of type 2 diabetes or a consequence of the …
The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and …
FK Knop, T Vilsbøll, PV Højberg, S Larsen… - Regulatory peptides, 2007 - Elsevier
BACKGROUND: The incretin effect is reduced and the insulinotropic effect of the incretin
hormone glucose-dependent insulinotropic polypeptide (GIP) is abolished in patients with …
hormone glucose-dependent insulinotropic polypeptide (GIP) is abolished in patients with …
Incretin‐based treatment of type 2 diabetes: glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors
CF Deacon - Diabetes, Obesity and Metabolism, 2007 - Wiley Online Library
Incretins are gut peptides that potentiate nutrient‐stimulated insulin secretion following meal
ingestion. Activities of the dominant incretins, glucagon‐like peptide‐1 (GLP‐1) and glucose …
ingestion. Activities of the dominant incretins, glucagon‐like peptide‐1 (GLP‐1) and glucose …
[PDF][PDF] Incretin hormones and beta cell function in chronic pancreatitis
FK Knop - Dan Med Bull, 2010 - content.ugeskriftet.dk
3. Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Holst JJ, Krarup T: The
insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary …
insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary …
DPP IV inhibitors-current evidence and future directions
T Vilsbøll, FK Knop - The British Journal of Diabetes & …, 2007 - journals.sagepub.com
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)
are responsible for the higher insulin response after oral versus intravenous glucose …
are responsible for the higher insulin response after oral versus intravenous glucose …